Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, outlines the development of bispecific chimeric antigen receptor T-cell (CAR-T) therapies that simultaneously target two tumor antigens. Bispecific CAR-T cells can overcome the resistance related to pre-treatment with targeted therapy or CAR-T cell therapy. These next-generation CAR-T cells are primarily being developed to treat patients who are relapsed or resistant to current CD19 CAR-T cell therapies. Clinical trials shall be undertaken to validate the effectiveness of bispecific CAR-T cell approaches. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
